Insider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) CTO Sells 2,151 Shares of Stock

Aura Biosciences, Inc. (NASDAQ:AURA) CTO Mark Plavsic sold 2,151 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total transaction of $16,670.25. Following the transaction, the chief technology officer now owns 209,456 shares in the company, valued at approximately $1,623,284. This represents a 1.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Aura Biosciences Trading Down 3.8 %

NASDAQ:AURA opened at $7.65 on Wednesday. The company has a market cap of $382.12 million, a PE ratio of -4.42 and a beta of 0.29. Aura Biosciences, Inc. has a twelve month low of $6.63 and a twelve month high of $12.38. The company’s 50 day moving average is $8.07 and its two-hundred day moving average is $8.76.

Wall Street Analyst Weigh In

Several brokerages have weighed in on AURA. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a research report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Aura Biosciences has an average rating of “Buy” and an average target price of $23.00.

Institutional Trading of Aura Biosciences

Large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets purchased a new stake in Aura Biosciences during the 4th quarter worth approximately $50,000. China Universal Asset Management Co. Ltd. purchased a new stake in Aura Biosciences during the 4th quarter worth approximately $87,000. ProShare Advisors LLC purchased a new stake in Aura Biosciences during the 4th quarter worth approximately $127,000. Harvest Investment Services LLC purchased a new stake in Aura Biosciences during the 4th quarter worth approximately $133,000. Finally, AlphaQuest LLC purchased a new stake in Aura Biosciences during the 4th quarter worth approximately $136,000. Hedge funds and other institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.